

# ENABLE: Medication brand changes in hormone therapy for breast cancer

<b>Submission date</b> 19/06/2024	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 25/06/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 22/08/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Annually, 55,900 women are diagnosed with invasive breast cancer. After completing surgery, chemotherapy or radiation, around 44,720 (80%) are prescribed hormone therapy (HT) drugs (tamoxifen, anastrozole, letrozole, exemestane). These drugs help in preventing the cancer coming back (recurrence) or spreading to other parts of the body (metastasis). When patients are prescribed HT they take it as a daily tablet, usually for five years and in some cases for up to ten. HT medication produces a considerable amount of side effects: hot flashes, depression, low sexual desire, joint pain, low energy and tiredness among other bothersome symptoms. As a consequence, some women stop taking the medication early (discontinue) or do not take it as prescribed (poor adherence). Around 50% of women have poor adherence by five years. There are many factors that influence women to completely stop or not take their HT drugs as indicated. Our preliminary research has identified that changing the medication brand name (generics) can be challenging for patients. It is common practice for community pharmacies to dispense a different generic of the same drug when patients collect their prescriptions. This can negatively impact many patients, who experience: new side effects, lack of information on generics, feel unsupported, and encounter disbelief from healthcare professionals. This affects in turn women's confidence in taking their medication, e.g. when women search for their preferred brand, they do not take the medication or stop taking it if they cannot find a brand that suits them. Pharmacists suggest that training and guidelines would be needed for them to support these patients. However, to date no effective intervention exists to address patients' concerns with HT generic switching.

**Aim:** Supported by a breast cancer patient advisory group and key stakeholders, we will co-produce an intervention to improve medication consultations about HT brand changes.

### Who can participate?

WP1 Community Pharmacists in London; Pharmacist representatives of professional bodies; owners or managers of community pharmacies; WP2 community pharmacists in London; WP3 Community pharmacists located in Barnet, Camden, Enfield, Haringey and Islington.

WP1 Women with breast cancer, taking HT medication or had taken these drugs in the last 12 months (and) has/had concerns about changing medication brands. WP3 Women diagnosed with early breast cancer [stage 1-3], taking HT medication, and have/had concerns about medication brand changes. Patients participating in co-development workshops will be recruited in London;

patients participating in the testing of the intervention will be recruited by community pharmacies located in the boroughs above.

What does the study involve?

WP1 Community Pharmacists will participate in 2 co-development workshops as researchers; Community pharmacists (owners or managers) and pharmacists representatives will participate in interviews about the barriers and facilitators of implementing the intervention; WP2 Community pharmacists will provide feedback after testing an e-learning package; WP3 Community pharmacists will attend an online training; recruit and consent 4 patients, collect data; deliver a medication consultation, take feedback notes; and participate in a follow-up interview.

WP1 Breast cancer patients will participate in 2 co-development workshops as researchers. WP3 Breast cancer patients will be recruited by community pharmacies, and will complete a diary (to record medication symptoms) for a minimum of 1 month and a maximum 3 months; attend a medication consultation with the community pharmacist; and a follow-up interview with the research team.

What are the possible benefits and risks of participating?

All participating pharmacists might find it useful to reflect on the management of HT medication consultations. They will have the opportunity to contribute their views on the prototype intervention and potentially help community pharmacists to better manage medication consultations and improve patients' adherence in the future. In addition, Pharmacists delivering the intervention they will gain research experience and gain CPD recognition. Potential risks: We do not envisage any significant risks arising for pharmacists. The main issue would be time constraints.

Patients: We cannot promise the study will benefit them immediately, but they might find it useful to explore a way of thinking around their HT medication brand that might help them better understand symptoms and side effects, and become more confident when discussing with pharmacists about new symptoms attributed to certain brands. Potential risks: During follow-up interviews, there might be cases when women feel upset when discussing their previous experiences and decisions made regarding therapy, whereby changing medications brands, describing new side effects or troubles in accessing a preferred brand could be upsetting.

Where is the study run from?

London Metropolitan University (UK)

When is the study starting and how long is it expected to run for?

March 2024 to March 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR) Research for Patient Benefit programme (UK)

Who is the main contact?

Prof Yolanda Eraso, [y.eraso@londonmet.ac.uk](mailto:y.eraso@londonmet.ac.uk)

## Contact information

Type(s)

Scientific, Principal investigator

**Contact name**

Prof Yolanda Eraso

**ORCID ID**

<https://orcid.org/0000-0002-7754-5960>

**Contact details**

School of Social Sciences and Professions, London Metropolitan University, 166-220 Holloway Road

London

United Kingdom

N7 8DB

+44 20 7133 2623

y.eraso@londonmet.ac.uk

## Additional identifiers

**Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

327926

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

CPMS 56605, NIHR206589, IRAS 327926

## Study information

**Scientific Title**

Medication brand changes in hormone therapy for breast cancer. A community pharmacy intervention development to improve patients' adherence and quality of life

**Acronym**

ENABLE

**Study objectives**

It is possible to co-develop a community pharmacy intervention to improve medication consultations about hormone therapy brand switching in women with breast cancer.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 03/07/2024, West Midlands – South Birmingham REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8121; southbirmingham.rec@hra.nhs.uk), ref: 24 /WM/0137

## **Study design**

Interventional qualitative

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Hormone therapy for breast cancer

## **Interventions**

WP 1: Intervention development

1a. A rapid scoping review of the literature to identify the best available evidence on patient medication diary interventions for cancer patients.

1b. Two co-design Workshops:

Co-production workshops with BC patients and pharmacists

i. WS1: Develop content for a patient self-management diary;

ii. WS2: Develop content for a medication consultation guide for pharmacists and training content.

1.c Qualitative interviews with pharmacists: We will explore the views of pharmacist representatives of professional bodies and owners of community pharmacies about the barriers and facilitators of implementing the intervention.

WP 2: Design of e-learning resource for pharmacists

2a. E-learning package design: A Web-developer specialist will collaborate in the design of an e-learning package based on the educational content of the prototype intervention.

2b. Qualitative interviews with pharmacists: Feedback will aim to establish the appropriateness of the educational intervention as a learning tool.

WP 3: Testing and optimisation studies

We will test the intervention to gather feedback from participants and optimise the different components as follows:

3a. Deliver of the e-learning package to 5 community pharmacists in North Central London ICS. Participants will access the e-learning for 1 month.

3b. The 5 trained pharmacists will recruit 20 (4 each) BC patients from their CPs. Eligible patients will receive a self management diary and will attend a medication consultation with the pharmacist. Follow-up interviews with participants.

3.c Integration of feedback to produce ENABLE, and a protocol for a feasibility study.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Qualitative interviews to optimise the usability, practicality and acceptability of the intervention for community pharmacists and breast cancer patients. Using behavioural analysis constructs from the Theoretical Domains Framework and the Person-Based Approach for intervention development conducted 2 or 3 weeks after the testing of the intervention in WP3

## **Key secondary outcome(s))**

There are no secondary outcome measures

**Completion date**

31/03/2026

## Eligibility

**Key inclusion criteria**

WP1 - 1.c Qualitative interviews with pharmacists:

1. Pharmacists who are owner or manager of a community pharmacy, chain and independent;
2. pharmacists with a representative role in professional pharmaceutical bodies, e.g. Local Pharmaceutical Committee, Community Pharmacy England, Royal Pharmaceutical Society.

WP2 - 2b. Qualitative interviews with pharmacists:

1. A pharmacist or pharmacist technician, permanent or locum (and)
2. Working in community pharmacies located in London (and)
3. Providing hormone therapy medication to clients

WP3 – Testing and optimisation studies

Pharmacists:

1. Pharmacists and pharmacy technicians; from the London boroughs of Barnet, Camden, Enfield, Haringey, or Islington
2. Providing Hormone Therapy medication to clients
3. Agree to participate in online training
4. Agree to recruit 4 patients from their pharmacy
5. Agree to deliver a medication consultation with recruited participants and audio record 1 consultation (with patient consent), and provide feedback notes of the consultation.
6. Agree to provide feedback in a study follow-up interview.
7. Is willing to provide written (signed and dated) informed consent.

Patients:

1. Women 18+ with early BC (stage 1-3);
2. Talking oral HT medication (tamoxifen, anastrozole, or letrozole) and had/have concerns about changing HT brands;
3. Not taking HT medication as neo-adjuvant or secondary metastatic BC;
4. Is willing and able to record notes on side effects and medication taken (diary) and attend a medication consultation with the CP;
5. Is willing and able to participate in a study follow-up interview (phone or video conference);
6. Is willing to provide a copy of the diary;
7. Is willing to be audio recorded during the pharmacy consultation;
8. Is willing to provide written (signed and dated) informed consent.

**Participant type(s)**

Patient, Health professional

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

WP1 - 1.c Qualitative interviews with pharmacists:

1. locum, technician, assistants, pharmacist not owner or manager
2. Pharmacists without a representative role in professional pharmaceutical bodies

WP2 - 2b. Qualitative interviews with pharmacists:

1. Accredited Checking Technician, assistants

WP3 – Testing and optimisation studies

Pharmacists:

1. Locum, Accredited Checking Technician, pharmacy assistants.

Patients:

1. Male
2. Currently or recently (last 6 months) involved in another research study where medication adherence is a primary outcome;
3. Have had in the last 6 months a medication review about changing brands of HT drugs.

**Date of first enrolment**

27/08/2024

**Date of final enrolment**

30/09/2025

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Pharmacy 1C**

126 Kentish Town Road

London

United Kingdom

NW1 9QB

**Study participating centre****Pharmacy 2H**

59a Broad lane

London

United Kingdom

N15 4DJ

**Study participating centre****Pharmacy 3I**

51 St Peters St  
London  
United Kingdom  
N1 8JR

**Study participating centre****Pharmacy 4B**

11 Sheaveshill Avenue  
London  
United Kingdom  
NW9 6RS

**Study participating centre****Pharmacy 5E**

109 Chase Side  
London  
United Kingdom  
EN2 6NL

## **Sponsor information**

**Organisation**

London Metropolitan University

**ROR**

<https://ror.org/00ae33288>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

NIHR Central Commissioning Facility (CCF)

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a publically available repository

## IPD sharing plan summary

Stored in publicly available repository

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Protocol file</a>	version 1.3	17/03/2025	07/07/2025	No	No